These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 7536209)

  • 1. A randomized, double blind, placebo-controlled trial on safety and efficacy of recombinant human insulin-like growth factor-I in children with growth hormone receptor deficiency.
    Guevara-Aguirre J; Vasconez O; Martinez V; Martinez AL; Rosenbloom AL; Diamond FB; Gargosky SE; Nonoshita L; Rosenfeld RG
    J Clin Endocrinol Metab; 1995 Apr; 80(4):1393-8. PubMed ID: 7536209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two-year treatment of growth hormone (GH) receptor deficiency with recombinant insulin-like growth factor I in 22 children: comparison of two dosage levels and to GH-treated GH deficiency.
    Guevara-Aguirre J; Rosenbloom AL; Vasconez O; Martinez V; Gargosky SE; Allen L; Rosenfeld RG
    J Clin Endocrinol Metab; 1997 Feb; 82(2):629-33. PubMed ID: 9024266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of recombinant human insulin-like growth factor I (IGF-I) therapy on the growth hormone-IGF system of a patient with a partial IGF-I gene deletion.
    Camacho-Hübner C; Woods KA; Miraki-Moud F; Hindmarsh PC; Clark AJ; Hansson Y; Johnston A; Baxter RC; Savage MO
    J Clin Endocrinol Metab; 1999 May; 84(5):1611-6. PubMed ID: 10323388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual hormonal replacement therapy with insulin and recombinant human insulin-like growth factor (IGF)-I in insulin-dependent diabetes mellitus: effects on the growth hormone/IGF/IGF-binding protein system.
    Thrailkill K; Quattrin T; Baker L; Litton J; Dwigun K; Rearson M; Poppenheimer M; Kotlovker D; Giltinan D; Gesundheit N; Martha P
    J Clin Endocrinol Metab; 1997 Apr; 82(4):1181-7. PubMed ID: 9100593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant human insulin-like growth factor I has significant anabolic effects in adults with growth hormone receptor deficiency: studies on protein, glucose, and lipid metabolism.
    Mauras N; Martinez V; Rini A; Guevara-Aguirre J
    J Clin Endocrinol Metab; 2000 Sep; 85(9):3036-42. PubMed ID: 10999782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term treatment with recombinant insulin-like growth factor (IGF)-I in children with severe IGF-I deficiency due to growth hormone insensitivity.
    Chernausek SD; Backeljauw PF; Frane J; Kuntze J; Underwood LE;
    J Clin Endocrinol Metab; 2007 Mar; 92(3):902-10. PubMed ID: 17192294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin-like growth factor-I treatment in primary growth hormone insensitivity: effect of recombinant human IGF-I (rhIGF-I) and rhIGF-I/rhIGF-binding protein-3 complex.
    Tonella P; Flück CE; Mullis PE
    Horm Res Paediatr; 2010; 73(2):140-7. PubMed ID: 20190552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Musculoskeletal effects of the recombinant human IGF-I/IGF binding protein-3 complex in osteoporotic patients with proximal femoral fracture: a double-blind, placebo-controlled pilot study.
    Boonen S; Rosen C; Bouillon R; Sommer A; McKay M; Rosen D; Adams S; Broos P; Lenaerts J; Raus J; Vanderschueren D; Geusens P
    J Clin Endocrinol Metab; 2002 Apr; 87(4):1593-9. PubMed ID: 11932288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant human growth hormone plus recombinant human insulin-like growth factor-1 coadministration therapy in short children with low insulin-like growth factor-1 and growth hormone sufficiency: results from a randomized, multicenter, open-label, parallel-group, active treatment-controlled trial.
    Backeljauw PF; Miller BS; Dutailly P; Houchard A; Lawson E; Hale DE; Reiner B; Sperling MA;
    Horm Res Paediatr; 2015; 83(4):268-79. PubMed ID: 25765099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic studies of recombinant human insulin-like growth factor I (rhIGF-I)/rhIGF-binding protein-3 complex administered to patients with growth hormone insensitivity syndrome.
    Camacho-Hübner C; Rose S; Preece MA; Sleevi M; Storr HL; Miraki-Moud F; Minuto F; Frystyk J; Rogol A; Allan G; Sommer A; Savage MO
    J Clin Endocrinol Metab; 2006 Apr; 91(4):1246-53. PubMed ID: 16403822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant human insulin-like growth factor I, recombinant human growth hormone, and sex steroids: effects on markers of bone turnover in humans.
    Mauras N; Doi SQ; Shapiro JR
    J Clin Endocrinol Metab; 1996 Jun; 81(6):2222-6. PubMed ID: 8964855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant human insulin-like growth factor-I therapy for children with growth disorders.
    Richmond EJ; Rogol AD
    Adv Ther; 2008 Dec; 25(12):1276-87. PubMed ID: 19066756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prolonged treatment with recombinant insulin-like growth factor-I in children with growth hormone insensitivity syndrome--a clinical research center study. GHIS Collaborative Group.
    Backeljauw PF; Underwood LE
    J Clin Endocrinol Metab; 1996 Sep; 81(9):3312-7. PubMed ID: 8784089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant insulin-like growth factor (IGF)-I treatment in short children with low IGF-I levels: first-year results from a randomized clinical trial.
    Midyett LK; Rogol AD; Van Meter QL; Frane J; Bright GM;
    J Clin Endocrinol Metab; 2010 Feb; 95(2):611-9. PubMed ID: 19880790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, placebo-controlled trial of combined insulin-like growth factor I and low dose growth hormone therapy for wasting associated with human immunodeficiency virus infection.
    Lee PD; Pivarnik JM; Bukar JG; Muurahainen N; Berry PS; Skolnik PR; Nerad JL; Kudsk KA; Jackson L; Ellis KJ; Gesundheit N
    J Clin Endocrinol Metab; 1996 Aug; 81(8):2968-75. PubMed ID: 8768860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose-dependent effects of recombinant human insulin-like growth factor (IGF)-I/IGF binding protein-3 complex on overnight growth hormone secretion and insulin sensitivity in type 1 diabetes.
    Saukkonen T; Amin R; Williams RM; Fox C; Yuen KC; White MA; Umpleby AM; Acerini CL; Dunger DB
    J Clin Endocrinol Metab; 2004 Sep; 89(9):4634-41. PubMed ID: 15356074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term effect of recombinant human insulin-like growth factor I on metabolic and growth control in a patient with leprechaunism.
    Nakae J; Kato M; Murashita M; Shinohara N; Tajima T; Fujieda K
    J Clin Endocrinol Metab; 1998 Feb; 83(2):542-9. PubMed ID: 9467572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin-like growth factor-I (rhIGF-I) therapy of short stature.
    Rosenbloom AL
    J Pediatr Endocrinol Metab; 2008 Apr; 21(4):301-15. PubMed ID: 18556960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunoblot studies of the acid-labile subunit (ALS) in biological fluids, normal human serum and in children with GH deficiency and GH receptor deficiency before and after long-term therapy with GH or IGF-I respectively.
    Labarta JI; Gargosky SE; Simpson DM; Lee PD; Argente J; Guevara-Aguirre J; Rosenfeld RG
    Clin Endocrinol (Oxf); 1997 Dec; 47(6):657-66. PubMed ID: 9497872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kinetics of insulin-like growth factor (IGF) and IGF-binding protein responses to a single dose of growth hormone.
    Lee PD; Durham SK; Martinez V; Vasconez O; Powell DR; Guevara-Aguirre J
    J Clin Endocrinol Metab; 1997 Jul; 82(7):2266-74. PubMed ID: 9215305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.